​

Arcturus Therapeutics Ownership | Who Owns Arcturus Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Arcturus Therapeutics Ownership Summary

Arcturus Therapeutics is owned by 94.96% institutional investors, 7.88% insiders. Federated hermes is the largest institutional shareholder, holding 17.35% of ARCT shares. Federated Hermes Kaufmann R is the top mutual fund, with 8.98% of its assets in Arcturus Therapeutics shares.

ARCT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockArcturus Therapeutics94.96%7.88%-2.83%
SectorHealthcare Stocks 487.91%11.08%-398.99%
IndustryBiotech Stocks 307.10%11.11%-218.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Federated hermes4.69M17.35%$79.66M
Blackrock funding, inc. /de2.64M9.74%$34.36M
Sumitomo mitsui trust1.95M7.18%$35.90M
Nikko asset management americas1.83M6.75%$23.79M
Ark investment management1.72M6.32%$22.31M
Vanguard group1.68M6.22%$28.59M
State street1.33M4.90%$22.50M
Balyasny asset management864.10K3.19%$11.24M
Schonfeld strategic advisors849.08K3.14%$14.41M
Woodline partners lp806.91K2.98%$13.69M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Ikarian capital175.00K0.44%$2.28M
Diametric capital, lp59.20K0.41%$770.13K
Green alpha advisors21.44K0.38%$395.19K
Nikko asset management americas1.83M0.24%$23.79M
Empire life investments264.01K0.22%$3.43M
Corton capital13.34K0.20%$173.53K
Federated hermes4.69M0.17%$79.66M
Ark investment management1.72M0.16%$22.31M
Diversify advisory services222.50K0.13%$3.31M
Belmont capital40.00K0.11%$678.80K

Top Buyers

HolderShares% AssetsChange
Schonfeld strategic advisors849.08K0.08%479.48K
Diversify advisory services222.50K0.13%204.50K
Sumitomo mitsui trust1.95M0.02%115.37K
Vanguard group1.68M0.00%107.64K
Alyeska investment group102.52K0.00%102.52K

Top Sellers

HolderShares% AssetsChange
Bioimpact capital---459.94K
Jupiter asset management---319.45K
Ark investment management1.72M0.16%-293.44K
Millennium management---236.07K
Vestal point capital, lp---211.79K

New Positions

HolderShares% AssetsChangeValue
Alyeska investment group102.52K0.00%102.52K$1.33M
Susquehanna portfolio strategies81.18K0.02%81.18K$1.06M
Eversept partners, lp48.36K0.06%48.36K$629.22K
Gateway investment advisers40.00K0.01%40.00K$737.20K
Arrowstreet capital, limited partnership37.53K0.00%37.53K$488.23K

Sold Out

HolderChange
Capital performance advisors llp-2.00
Frazier financial advisors-4.00
Gps wealth strategies group-10.00
Geowealth management-19.00
Smartleaf asset management-30.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20251542.67%25,761,135-3.22%940.98%7814.71%42-14.29%
Mar 31, 2025148-5.73%26,589,017-0.21%981.01%67-4.29%494.26%
Dec 31, 2024155-9.36%26,627,1731.41%981.05%69-14.81%47-6.00%
Sep 30, 2024170-4.49%26,254,877-0.08%971.02%815.19%49-27.94%
Jun 30, 2024178-5.82%26,276,502-3.48%970.95%77-15.38%6811.48%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Federated Hermes Kaufmann R2.44M8.98%-
Federated Hermes Kaufmann Growth2.44M8.98%-
Federated Hermes Kaufmann Small Cap Grow2.20M8.10%-
Federated Hermes Kaufmann Small Cap A2.20M8.10%-
ARK Genomic Revolution1.68M6.17%-301.26K
ARK Genomic Revolution ETF1.67M6.16%-5.97K
Nikko AM ARK Pstv Chg Innovt P JPY Acc1.61M5.93%-56.86K
Amova ARK Pstv Chg Innovt P JPY Acc1.52M5.61%-86.53K
Vanguard US Total Market Shares ETF723.64K2.67%-
Vanguard Total Stock Mkt Idx Inv709.09K2.61%-15.64K

Recent Insider Transactions

DateNameRoleActivityValue
Aug 15, 2025SASSINE ANDY Chief Financial OfficerBuy$20.50K
Aug 15, 2025SASSINE ANDY Chief Financial OfficerSell$20.50K
Oct 15, 2024Chivukula Pad Chief Scientific Officer & COOSell$249.12K
Jun 12, 2024SASSINE ANDY Chief Financial OfficerSell$1.60M
Jun 05, 2024Chivukula Pad Chief Scientific Officer & COOSell$5.13K

Insider Transactions Trends

DateBuySell
2025 Q2--
2024 Q4-1
2024 Q2-3
2024 Q1-2
2023 Q4-2

ARCT Ownership FAQ

Who Owns Arcturus Therapeutics?

Arcturus Therapeutics shareholders are primarily institutional investors at 94.96%, followed by 7.88% insiders and -2.84% retail investors. The average institutional ownership in Arcturus Therapeutics's industry, Biotech Stocks , is 307.10%, which Arcturus Therapeutics falls below.

Who owns the most shares of Arcturus Therapeutics?

Arcturus Therapeutics’s largest shareholders are Federated hermes (4.69M shares, 17.35%), Blackrock funding, inc. /de (2.64M shares, 9.74%), and Sumitomo mitsui trust (1.95M shares, 7.18%). Together, they hold 34.26% of Arcturus Therapeutics’s total shares outstanding.

Does Blackrock own Arcturus Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Arcturus Therapeutics.

Who is Arcturus Therapeutics’s biggest shareholder by percentage of total assets invested?

Ikarian capital is Arcturus Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.44% of its assets in 175K Arcturus Therapeutics shares, valued at 2.28M$.

Who is the top mutual fund holder of Arcturus Therapeutics shares?

Federated Hermes Kaufmann R is the top mutual fund holder of Arcturus Therapeutics shares, with 8.98% of its total shares outstanding invested in 2.44M Arcturus Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools